EGTX — Egetis Therapeutics AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK2.11bn
- SEK1.97bn
- SEK62.40m
Swedisg drugmaker Egetis's Q1 revenue rises 9% on Emcitate sales in Europe
Brief: Egetis Therapeutics Q1 Loss SEK 94.5 Mln
Brief: Egetis Plans Directed Share Issue Raising SEK 350 Million
Brief: Egetis Therapeutics Appoints Tiago Nunes As CMO Effective May 1
Brief: Egetis Gets Conditional FDA Name Acceptance
Brief: Egetis Announces Priority Review Of NDA For Emcitate (Tiratricol) For MCT8 Deficiency
Brief: Egetis Gets Notice Of Allowance For Patent In The U.S.
Brief: Egetis Therapeutics FY Revenue At SEK 62.3 Million, Below IBES Estimate
Sweden's Egetis revenue up 40% but misses estimates
Brief: Egetis Says FDA's Rare Pediatric Disease Priority Review Program Extended Until 2029
Brief: Egetis Completes U.S. Rolling NDA Submission For Emcitate
Brief: Egetis Therapeutics Chairman Acquires Shares
Brief: Egetis Therapeutics Initiates Rolling NDA Submission To FDA For Emcitate
Brief: Egetis And Er-Kim Expand Partnership
Brief: Egetis Therapeutics CFO Acquired SEK 899,125 Worth Of Co Share
Brief: Egetis Therapeutics Chairman Bought Co Shares
Brief: Egetis Therapeutica Board Chairman Buys SEK 943,200 Worth Of Co's Shares
Brief: Egetis Therapeutics 9M Adjusted EPS SEK -0.6
Brief: Egetis Granted Rolling NDA Review By FDA For Emcitate®